Podcast Episodes
Back to SearchPalantir (PLTR): Revenue Grew 93% — Bookings Grew 49%. Is PLTR a Buy After Q2 2026?
Palantir Technologies Inc. (PLTR) Q2 2026 — Reported after the close on August 3 (the three months ended June 30, 2026). Revenue $1,935.5M, up 92.8% …
3 months ago
Old Dominion (ODFL): Record Operating Ratio — 91% Of The Growth Was Diesel. Is ODFL a Buy?
Old Dominion Freight Line, Inc. (ODFL) Q2 2026 — Reported before the open on July 29 (Q2 2026, the three months ended June 30, 2026). Revenue $1,554.…
3 months ago
O’Reilly (ORLY): A 6% Comp — And The Operating Margin FELL. Is ORLY a Buy?
O'Reilly Automotive, Inc. (ORLY) Q2 2026 — Reported after the close on July 29 (Q2 2026, the three months ended June 30, 2026). Sales $4,892.0M, up 8…
3 months ago
Royal Caribbean (RCL): Revenue +6.5%, Earnings DOWN. Is RCL a Buy?
Royal Caribbean Cruises Ltd. (RCL) Q2 2026 — Reported before the open on July 28 (Q2 2026, the three months ended June 30, 2026). Total revenue $4,83…
3 months ago
MakeMyTrip (MMYT): Bookings +19.9%, Profit -65%. Is MMYT a Buy?
MakeMyTrip Limited (MMYT) Q1 FY2027 — Reported August 3 (Q1 FY2027, the three months ended June 30, 2026 — MakeMyTrip's fiscal year ends 31 March, so…
3 months ago
EchoStar (ECHO): $24.12 EPS Came From A Bankruptcy. Is ECHO a Buy?
EchoStar Corporation (ECHO) Q2 2026 — Reported August 3 (Q2 2026, the three months ended June 30, 2026). Total revenue $3.576B, DOWN 4.0% from $3.725…
3 months ago
TG Therapeutics (TGTX): Revenue +70% And Operating Income FELL. Is TGTX a Buy?
TG Therapeutics, Inc. (TGTX) Q2 2026 — Reported before the open (Q2 2026, the three months ended June 30, 2026). Total revenue $240.3M, +70.3% — a ~$…
3 months ago
Twist Bioscience (TWST): Revenue +23% And The Loss Got BIGGER. Is TWST a Buy?
Twist Bioscience Corporation (TWST) Q3 FY2026 — Reported before the open (fiscal Q3 2026, the three months ended June 30, 2026). Revenue $118.4M, +23…
3 months ago
CNH Industrial (CNH): Profit Fell 35% And The Stock ROSE 8%. Is CNH a Buy?
CNH Industrial N.V. (CNH) Q2 2026 — Reported before the open (three months ended June 30, 2026). Consolidated revenues $4,803M, +2% (FLAT at constant…
3 months ago
Krystal Biotech (KRYS): US Sales FELL On A 24% Beat. Is KRYS a Buy?
Krystal Biotech, Inc. (KRYS) Q2 2026 — Reported before the open (three months ended June 30, 2026). Revenue $119.222M, +24.1%, just UNDER a ~$120.9M …
3 months ago